News
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...
As weight loss medications, including Ozempic and WeGovy, have gained popularity across the U.S., they are not without side effects, some serious. According to a May 2024 CNN report, as many as 1 in 8 ...
Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But the company ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...
One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics ' ( VKTX 0.32%) stock in ...
As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...
18h
MedPage Today on MSNWegovy Pill Under Review; FDA Lifts Obesity Trial Clinical Hold; SGLT2s and SurgeryThe FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...
But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...
This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results